Comparison - Mirvaso with Rhofade

[Guide]

Brimonidine (Mirvaso) and oxymetazoline (Rhofade) are both topical α-adrenergic agonists that have been developed to treat the persistent erythema of rosacea patients. Pharmacological profiling showed brimonidine to be highly selective for the α2 adrenergic receptors, whereas oxymetazoline was much less selective with a significant number of off-target activities, including the 5-hydroxytryptamine 2B (5-HT2B) serotonin receptor.

As the 5-HT2B receptor is potentially involved in drug-induced valvulopathy, the benefit/risk ratio should be carefully considered, especially in patients with cardiovascular disease or other comorbidities.

Drugs in R&D
March 2018, Volume 18, Issue 1, pp 87–90 | Cite as
In Vitro Safety Pharmacology Profiling of Topical α-Adrenergic Agonist Treatments for Erythema of Rosacea
David Piwnica, Atul Pathak, Gregor Schäfer, James R. Docherty